Orange Grove Bio (“OGB”) is a preclinical drug investment and development platform focused on driving down the cost of drug discovery and advancing therapies into clinical trials.
We are partnered with leading universities to license transformational medicines. Orange Grove Bio and its university partners streamline the licensing process to speed up the development process to get drugs to market faster and to save time on-patent.
Orange Grove also sources programs through investment in preclinical stage biotech companies. Orange Grove Bio's experienced development team works with these companies to more efficiently advance programs into the clinic and hit additional value-inflection points.
We have a particular interest in oncology, inflammatory, and autoimmune disease treatments, and work across all different therapeutic modalities.
Regardless of the approach, our mission is to work to bring forward more treatments to treat patients and cure disease.